-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with non-small cell lung cancer ( NSCLC ) accounting for 85% of all lung cancers
Lung cancer is one of the leading causes of cancer-related deaths worldwide, with non-small cell lung cancer ( NSCLC ) accounting for 85% of all lung cancers
Previous studies have shown that the ERBB family plays a crucial role in basic cellular functions, regulating the activation of various downstream signaling pathways such as cell proliferation, differentiation, survival, and migration
EGFR mutations are one of the most common oncogenic drivers in NSCLC, and EGFR has also been identified as a potential target for targeted therapy
EGFR mutations are one of the most common oncogenic drivers in NSCLC, and EGFR has also been identified as a potential target for targeted therapy
In this study, researchers identified a more potent EGFR mutation-selective allosteric inhibitor, JBJ-09-063, and explored its efficacy
We identified a more potent EGFR mutation-selective allosteric inhibitor, JBJ-09-063, and explored its efficacy
Our findings reveal the potential clinical efficacy of JBJ-09-063 as a single agent or in combination with EGFR TKIs, and identify more effective treatment strategies for EGFR-mutant lung cancer
To, C.
, Beyett, TS, Jang, J.
et al.
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
Nat Cancer (14 April 2022).
https://doi.
org/10.
1038/s43018-022-00351-8.
Leave a message here
